Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Bariatrics Boom

Executive Summary

Over the last 20 years, obesity has become a disease of epidemic proportions, and the prevalence of this complex disease continues to rise. Amid this epidemic, opportunities abound for companies with surgical and nonsurgical solutions, making this market one of the hottest new growth areas for medical technology companies. At this year's meeting of the American Society of Bariatric Surgery (ASBS), manufacturers showcased some of the latest surgical solutions for treating obesity and the morbidly obese.

You may also be interested in...



Satiety: Treating Obesity Beyond Quality of Life

Obesity is no longer merely a lifestyle-related condition; it's a worldwide epidemic with life-threatening consequences. Satiety is developing a device-based alternative to surgery that could expand the market for both physicians and patients.

EnteroMedics' Weighty Financing for Obesity

EnteroMedics recently earned the distinction of closing the second-largest financing for a private medical device company in 2006. Its success was undoubtedly due to the company's attractive position at the junction of two of the device industry's hottest markets: obesity and neuromodulation. EnteroMedics is developing an implantable impulse generator that it hopes will address multiple mechanisms in obesity.

Positioning Acomplia: Has the Drug Arrived Before the Disease?

Sanofi-Aventis is the envy of many as it awaits approval for fat-busting metabolic syndrome drug, Acomplia. But obesity is rarely reimbursed; metabolic syndrome still undefined.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel